ClinicalTrials.gov GLP-1 trial tracker — updated weekly

Posting this as an important update for the clinical trials & research community. Please read carefully as this may affect your current plans.

I will keep this thread updated as new information becomes available. If you have additional information or corrections, please post below and I will incorporate confirmed updates into this OP.

Key points:

• This information is current as of the date posted
• Circumstances may change — always verify independently
• If you have questions, check if they have been answered in the replies before posting

Bookmarking this thread is recommended — it will be updated as the situation evolves.

As a healthcare provider, I want to add some clinical context to this discussion on ClinicalTrials.gov GLP-1 trial tracker .

Building on what TrialTracker_MD said — the evidence base here is well-established. The key publications to reference are from the STEP program[1].

Key clinical points:

1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
2. Side effect profile is predictable and usually manageable with standard protocols
3. Monitoring should include baseline labs and follow-up at 3-month intervals
4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

+1 to LindaRN_retired. Especially the point about "gov GLP-1 trial tracker..." — I have seen the same in my own experience with ClinicalTrials.gov GLP-1.

Adding my data to this ClinicalTrials.gov GLP-1 discussion:

Protocol: Tirzepatide 15mg/wk, resistance training 3x/wk, protein 1.4g/kg/day.

LindaRN_retired said:

gov GLP-1 trial tracker

Gonna push back on this one. ClinicalTrials.gov GLP-1 trial is not that straightforward in my experience. I have been on this for 12 months and the reality is messier than the trials suggest.

Don't get me wrong — the medication works. But cost accessibility is a real barrier. We should be honest about that.